{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-071942","form_type":"8-K","ticker":"CABA","cik":"0001759138","company_name":"Cabaletta Bio, Inc.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.436108+00:00","generated_at":"2026-06-18T00:44:48.603424+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cabaletta Bio Q4 2022: cash $106.5M, CABA-201 IND expected H1 2023, data H1 2024","bullets":["R&D expenses $12.4M (Q4) and $39.3M (FY2022), up from $9.9M and $32.5M YoY.","Cash and investments $106.5M at Dec 31, 2022; funding expected into Q1 2025.","CABA-201 IND clearance expected H1 2023; initial clinical data anticipated H1 2024.","Raised $32.6M net in December 2022 public offering of pre-funded warrants and common stock.","DSG3-CAART combination sub-study data (1-month) expected H1 2023; MuSK-CAART trial initiated Nov 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-071942","json":"https://secwatch.observer/filing/0001193125-23-071942.json","markdown":"https://secwatch.observer/filing/0001193125-23-071942.md","text":"https://secwatch.observer/filing/0001193125-23-071942.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759138/000119312523071942/0001193125-23-071942-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759138/000119312523071942/d409494d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:44:48.603424+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5c64586418d41ae99953636c10c1d6e13b6ef7a8","claim":"Cabaletta Bio, Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2022.","evidence_excerpt":"On March 16, 2023, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the fourth quarter and fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000119312523071942/0001193125-23-071942-index.htm","confidence":0.5,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and fiscal year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}